The influenza vaccine is recommended for the following groups:

• Adults aged 75 and older
• Individuals aged 6 months to 74 years with:
  • Chronic heart or lung disease (including bronchopulmonary dysplasia, cystic fibrosis, and asthma)
  • Chronic conditions such as diabetes, inherited metabolic disorders (e.g., hereditary tyrosinemia type I), severe obesity (BMI ≥ 40), liver disease (including cirrhosis), kidney disease, blood disorders (including asplenia, anemia, or hemoglobinopathy), cancer, immune deficiency or immunosuppression (including HIV infection)
  • Medical conditions that reduce the ability to clear respiratory secretions or increase the risk of aspiration (e.g., cognitive impairment, spinal cord injury, seizure disorders, neuromuscular disorders)
• Residents of all ages in long-term care facilities (CHSLDs) and intermediate/specialized care residences (RI-SAPA)
• Children and adolescents under 18 receiving long-term treatment with acetylsalicylic acid (ASA)
• Pregnant women:
  • With one of the above conditions (vaccination is recommended at any stage of pregnancy)
  • In good health but in their 2nd or 3rd trimester (13 weeks or more)
• Travellers with one of the above conditions who are going to regions where influenza viruses are circulating
• Adults aged 65 to 74 years
• People who could transmit influenza to high-risk individuals, including:
  • Health care workers
  • Household contacts and caregivers of people at high risk of influenza complications
• People living in remote or isolated communities, with priority given to those at high risk of complications 

Pneumovax 23

• Recommended for adults aged 65 and older, except those with a condition considered very high risk for invasive pneumococcal disease (IPD)
• Recommended for adults aged 18 to 64 with a condition considered high risk for IPD

Prevnar 20
Recommended for people with one of the following very high–risk conditions for IPD:

• Anatomical or functional asplenia (see Practical Vaccinology: Asplenia)
• Immunosuppression (see Practical Vaccinology: Immunosuppression)
• Cirrhosis
• End-stage renal disease (including dialysis) or nephrotic syndrome
• Cochlear implant
• Chronic cerebrospinal fluid leakage
• Homelessness
• Current, regular use of hard drugs by inhalation or injection, associated with deteriorating health or precarious living conditions

Also recommended for:

• Adults aged 50 and older living in Indigenous communities of Nunavik and the Cree Territory of James Bay
• Adults aged 18 to 49 living in the same communities who also have one of the conditions listed above 

The COVID-19 vaccine is recommended for:

• Residents of long-term care facilities (CHSLDs), private seniors’ residences (RPAs), or other collective living environments with a high proportion of older or vulnerable individuals
• Adults aged 65 and older
• Individuals aged 6 months to 64 years who are immunocompromised, on dialysis, or living with a chronic illness
• Adults aged 18 and older living in remote or isolated communities
• Pregnant women
• Health care workers 

The RSV vaccine is recommended for:

• Residents aged 60 and older living in long-term care facilities (CHSLDs) or intermediate/specialized care residences (RI-SAPA)
• Residents aged 75 and older living in private seniors’ residences (RPAs) of categories 3 or 4:
  • Category 3: RPAs with personal assistance services and medication administration
  • Category 4: RPAs with nursing care 

The shingles vaccine is recommended for:

• Immunocompromised adults aged 18 and older
• Adults aged 75 and older